tirzepatide (Mounjaro)
Adjunctive therapy • Brands: MOUNJARO
Last reviewed: 2026-02-12
General information
- Primary label indications include: Type 2 diabetes mellitus (adjunct to diet/exercise) (label).
- Class: Adjunctive therapy
- Common US brands: MOUNJARO
- Therapeutic drug monitoring not routinely recommended.
- Last reviewed: 2026-02-12
Dosing & forms
- Forms/strengths: —
- Frequency: —
- Food: —
- Typical range: —
Mechanism (brief)
Weekly injectable dual [[GIP]]/[[GLP-1]] receptor agonist (tirzepatide) indicated for type 2 diabetes. It produces substantial weight loss in many patients, which can be relevant when metabolic comorbidity complicates psychiatric care, but it has no FDA-approved psychiatric indications.
Metabolism & Half‑life
- Metabolism: Proteolytic cleavage of the peptide backbone
- Half‑life: Single-dose mean 120 h
Therapeutic Drug Monitoring (TDM)
Recommended: No
Monitoring highlights
- —
Sources
- MOUNJARO (tirzepatide) injection prescribing information — DailyMed (2026)
- Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes — New England Journal of Medicine (2021)
- Tirzepatide once weekly for the treatment of obesity — New England Journal of Medicine (2022)
- Therapeutic management of atypical antipsychotic-related metabolic dysfunctions using GLP-1 receptor agonists: a systematic review — Experimental and Therapeutic Medicine (2023)